Law
Seminars International (LSI) will be offering a one-hour telebriefing entitled
"FTC v. Actavis: Practical Implications of the Landmark
Supreme Court Decision" on July 16, 2013 from 3:00 to 4:00
pm (Eastern). Jarod M. Bona of DLA Piper
will moderate a panel that includes Markus H. Meier, Assistant Director, Health
Care Division, Bureau of Competition, Federal Trade Commission; and Rohit K.
Singla of Munger Tolles & Olson LLP.
The panel will discuss the practical implications of this landmark case
and related antitrust issues involving pharmaceutical patents. Among the topics to be covered are:
•
Practical tips for drafting patent-settlement agreements going forward
•
FTC perspective on reverse-payment settlements and the underlying litigation of
the decision
•
Possible implications beyond pharmaceutical-patent settlements
•
Likely impacts on future litigation and patent settlements
A
Q&A will follow the presentation and last for up to 30 minutes.
The
registration fee is $150 per caller and $100 for each additional person on the
same line who desires continuing education credit. Those interested in registering for the
telebriefing, can do so here.
Comments